[1] |
Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa[J]. Nature, 2022,doi: 10.1038/s41586-022-04411-y.
|
[2] |
Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2 Omicron (B. 1.1. 529) variant of concern and its global perspective[J]. Journal of Medical Virology, 2022, 94(4): 1738 – 1744. doi: 10.1002/jmv.27524
|
[3] |
Liu JY, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron[J]. Nature, 2022,doi: 10.1038/s41586-022-04465-y.
|
[4] |
World Health Organization. COVID-19 Weekly epidemiological update[EB/OL].(2022 – 02 – 22).https://www.who.int/publications/m/item/weekly-epidemio-logical-update-on-covid-19---22-february-2022.
|
[5] |
李文艳, 杜志成, 王莹, 等. 新型冠状病毒Delta变异株引起的广州市荔湾区本土疫情流行特征分析[J]. 中华流行病学杂志, 2021, 42(10): 1763 – 1768. doi: 10.3760/cma.j.cn112338-20210613-00472
|
[6] |
Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021[J]. Eurosurveillance, 2021, 26(50): 2101147. doi: 10.2807/1560-7917.ES.2021.26.50.2101147
|
[7] |
Zheng J, Wang ZY, Li JM, et al. High amounts of SARS-CoV-2 in aerosols exhaled by patients with Omicron variant infection[J]. The Journal of Infection, 2022,doi: 10.1016/j.jinf.2022.02.015.
|
[8] |
Peacock TP, Brown JC, Zhou J, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry[J]. bioRxiv, 2022,doi: 10.1101/2021.12.31.474653.
|
[9] |
王莹, 尤心怡, 王奕婧, 等. 中国新型冠状病毒肺炎疫情基本再生数评估[J]. 中华流行病学杂志, 2020, 41(4): 476 – 479. doi: 10.3760/cma.j.cn112338-20200210-00086
|
[10] |
Garrett N, Tapley A, Andriesen J, et al. High rate of asymptomatic carriage associated with variant strain omicron[J]. medRxiv, 2022,doi: 10.1101/2021.12.20.21268130.
|
[11] |
Kim MK, Lee B, Choi YY, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea[J]. Journal of Korean Medical Science, 2022, 37(3): e31. doi: 10.3346/jkms.2022.37.e31
|
[12] |
Meo SA, Meo AS, AL-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical charac-teristics[J]. European Review for Medical and Pharmacological Sciences, 2021, 25(24): 8012 – 8018. doi: 10.26355/eurrev_202112_27652
|
[13] |
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: a prospective observa-tional study[J]. medRxiv, 2022, doi: 10.1101/2022.02.06.22270558.
|
[14] |
Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022,doi: 10.1038/s41586-022-04479-6.
|
[15] |
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 2022,doi: 10.1038/s41586-022-04462-1.
|
[16] |
Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas[J]. The American Journal of Pathology, 2022,doi: 10.1016/j.ajpath.2022.01.007.
|
[17] |
Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants[J]. Nature Medicine, 2022,doi: 10.1038/s41591-022-01753-y.
|